Xilio Therapeutics (XLO) Cash from Operations Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 158.60% |
| 10 | Xilio Therapeutics | 145.98 Mn | -4.32 Mn | - | -177.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.10% |
| Dec 31, 2025 | 85.89% |
| Sep 30, 2025 | -27.96% |
| Jun 30, 2025 | -172.56% |
| Mar 31, 2025 | 375.93% |
| Dec 31, 2024 | -5.44% |
| Sep 30, 2024 | -2.27% |
| Jun 30, 2024 | 220.39% |
| Mar 31, 2024 | 58.41% |
| Dec 31, 2023 | 26.32% |
| Sep 30, 2023 | 32.85% |
| Jun 30, 2023 | 1.09% |
| Mar 31, 2023 | -21.19% |
| Dec 31, 2022 | -6.18% |
| Sep 30, 2022 | 3.91% |
| Jun 30, 2022 | 16.79% |
| Mar 31, 2022 | 8.35% |
| Dec 31, 2021 | -35.08% |